Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 429

1.

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam SS, Vansteenkiste J.

J Clin Oncol. 2018 Aug 28:JCO2018783118. doi: 10.1200/JCO.2018.78.3118. [Epub ahead of print]

PMID:
30153097
2.

Complete genome of streamlined marine actinobacterium Pontimonas salivibrio strain CL-TW6T adapted to coastal planktonic lifestyle.

Cho BC, Hardies SC, Jang GI, Hwang CY.

BMC Genomics. 2018 Aug 22;19(1):625. doi: 10.1186/s12864-018-5019-9.

3.

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.

Drilon A, Ou SI, Cho BC, Kim DW, Lee J, Lin JJ, Zhu VW, Ahn MJ, Camidge DR, Nguyen J, Zhai D, Deng W, Huang Z, Rogers E, Liu J, Whitten J, Lim JK, Stopatschinskaja S, Hyman DM, Doebele RC, Cui JJ, Shaw AT.

Cancer Discov. 2018 Aug 9. doi: 10.1158/2159-8290.CD-18-0484. [Epub ahead of print]

PMID:
30093503
4.

Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer.

Cho BC, Dy GK, Govindan R, Kim DW, Pennell NA, Zalcman G, Besse B, Kim JH, Koca G, Rajagopalan P, Langer S, Ocker M, Nogai H, Barlesi F.

Lung Cancer. 2018 Sep;123:14-21. doi: 10.1016/j.lungcan.2018.04.022. Epub 2018 Apr 27.

5.

Discharge Hemoglobin Level and 30-Day Readmission Rates After Coronary Artery Bypass Surgery.

Cho BC, DeMario VM, Grant MC, Hensley NB, Brown CH 4th, Hebbar S, Mandal K, Whitman GJ, Frank SM.

Anesth Analg. 2018 Jul 27. doi: 10.1213/ANE.0000000000003671. [Epub ahead of print]

PMID:
30059402
6.

Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy.

Lee JS, Lee KH, Cho EK, Kim DW, Kim SW, Kim JH, Cho BC, Kang JH, Han JY, Min YJ, Park K.

Lung Cancer. 2018 Aug;122:234-242. doi: 10.1016/j.lungcan.2018.05.023. Epub 2018 May 24.

7.

Ultracentral Tumors Treated With Stereotactic Body Radiotherapy: Single-Institution Experience.

Raman S, Yau V, Pineda S, Le LW, Lau A, Bezjak A, Cho BCJ, Sun A, Hope AJ, Giuliani M.

Clin Lung Cancer. 2018 Sep;19(5):e803-e810. doi: 10.1016/j.cllc.2018.06.001. Epub 2018 Jun 18.

PMID:
30007498
8.

Identification of local clusters of mutation hotspots in cancer-related genes and their biological relevance.

Rhee JK, Yoo J, Kim KR, Kim J, Lee YJ, Cho BC, Kim TM.

IEEE/ACM Trans Comput Biol Bioinform. 2018 Mar 16. doi: 10.1109/TCBB.2018.2813375. [Epub ahead of print]

PMID:
29993813
9.

Can We Prevent Resistance to Osimertinib? Combination or Sequential.

Kim MH, Lim SM, Lee K, Soo RA, Cho BC.

J Thorac Oncol. 2018 Jul;13(7):877-879. doi: 10.1016/j.jtho.2018.05.012. No abstract available.

PMID:
29935843
10.

Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice.

Park S, Ahn BC, Lim SW, Sun JM, Kim HR, Hong MH, Lee SH, Ahn JS, Park K, Choi Y, Cho BC, Ahn MJ.

J Thorac Oncol. 2018 Sep;13(9):1373-1382. doi: 10.1016/j.jtho.2018.05.026. Epub 2018 Jun 5.

PMID:
29883837
11.

Sex Differences in Pedobarographic Findings and Relationship between Radiographic and Pedobarographic Measurements in Young Healthy Adults.

Koo S, Chun S, Lee KM, Cho BC, Koo YJ, Kang DW, Park MS.

Clin Orthop Surg. 2018 Jun;10(2):216-224. doi: 10.4055/cios.2018.10.2.216. Epub 2018 May 18.

12.

RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-κB-mediated ERK reactivation.

Cho JH, You YM, Yeom YI, Lee DC, Kim BK, Won M, Cho BC, Kang M, Park S, Yang SJ, Kim JS, Kim JA, Park KC.

Cell Death Dis. 2018 May 22;9(6):587. doi: 10.1038/s41419-018-0651-5.

13.

Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma.

Lim SM, Cho SH, Hwang IG, Choi JW, Chang H, Ahn MJ, Park KU, Kim JW, Ko YH, Ahn HK, Cho BC, Nam BH, Chun SH, Hong JH, Kwon JH, Choi JG, Kang EJ, Yun T, Lee KW, Kim JH, Kim JS, Lee HW, Kim MK, Jung D, Kim JE, Keam B, Yun HJ, Kim S, Kim HR.

Cancer Res Treat. 2018 May 9. doi: 10.4143/crt.2018.012. [Epub ahead of print]

14.

CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study.

Vansteenkiste J, Reungwetwattana T, Nakagawa K, Cho BC, Dols MAC, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam S.

Ann Oncol. 2017 Nov 1;28(suppl_10). doi: 10.1093/annonc/mdx782. No abstract available.

PMID:
29718073
15.

Surgical indication of Furlow palatoplasty to treat submucous cleft palate.

Kwon JH, Lee JW, Yang JD, Chung HY, Cho BC, Choi KY.

J Craniomaxillofac Surg. 2018 Jun;46(6):947-952. doi: 10.1016/j.jcms.2018.02.015. Epub 2018 Mar 29.

PMID:
29709332
16.

Low Incidence of Esophageal Toxicity After Lung Stereotactic Body Radiation Therapy: Are Current Esophageal Dose Constraints Too Conservative?

Yau V, Lindsay P, Le L, Lau A, Wong O, Glick D, Bezjak A, Cho BCJ, Hope A, Sun A, Giuliani M.

Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):574-580. doi: 10.1016/j.ijrobp.2018.02.025. Epub 2018 Mar 2.

PMID:
29680259
17.

Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors.

Yun MR, Lim SM, Kim SK, Choi HM, Pyo KH, Kim SK, Lee JM, Lee YW, Choi JW, Kim HR, Hong MH, Haam K, Huh N, Kim JH, Kim YS, Shim HS, Soo RA, Shih JY, Yang JC, Kim M, Cho BC.

Cancer Res. 2018 Jun 15;78(12):3350-3362. doi: 10.1158/0008-5472.CAN-17-3146. Epub 2018 Apr 18.

PMID:
29669761
18.

Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea.

Choi MK, Ahn JS, Kim YC, Cho BC, Oh IJ, Kim SW, Lee JS, Kim JH, Ahn MJ, Park K.

Lung Cancer. 2018 May;119:36-41. doi: 10.1016/j.lungcan.2018.02.020. Epub 2018 Mar 6.

PMID:
29656750
19.

Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01).

Ku BM, Heo MH, Kim JH, Cho BC, Cho EK, Min YJ, Lee KH, Sun JM, Lee SH, Ahn JS, Park K, Kim TJ, Lee HY, Kim H, Lee KJ, Ahn MJ.

J Pathol Transl Med. 2018 May;52(3):148-156. doi: 10.4132/jptm.2018.03.12. Epub 2018 Mar 26.

20.

Histopathological Findings After Reirradiation Compared to First Irradiation of Spinal Bone Metastases With Stereotactic Body Radiotherapy: A Cohort Study.

Foerster R, Cho BCJ, Fahim DK, Gerszten PC, Flickinger JC, Grills IS, Jawad MS, Kersh CR, Létourneau D, Mantel F, Sahgal A, Shin JH, Winey BA, Guckenberger M.

Neurosurgery. 2018 Mar 14. doi: 10.1093/neuros/nyy059. [Epub ahead of print]

PMID:
29547929
21.

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.

Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Huang Y, Wadsworth C, Dennis PA, Rizvi NA; ATLANTIC Investigators.

Lancet Oncol. 2018 Apr;19(4):521-536. doi: 10.1016/S1470-2045(18)30144-X. Epub 2018 Mar 12.

PMID:
29545095
22.

A murine model of radiation-induced capsule-tissue reactions around smooth silicone implants.

Kim JB, Jeon HJ, Lee JW, Choi KY, Chung HY, Cho BC, Park SH, Park MH, Bae JS, Yang JD.

J Plast Surg Hand Surg. 2018 Aug;52(4):217-224. doi: 10.1080/2000656X.2018.1444617. Epub 2018 Mar 9.

PMID:
29523044
23.

Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies.

Lim SM, Syn NL, Cho BC, Soo RA.

Cancer Treat Rev. 2018 Apr;65:1-10. doi: 10.1016/j.ctrv.2018.02.006. Epub 2018 Feb 20. Review.

PMID:
29477930
24.

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.

Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L.

Ann Oncol. 2018 Jan 1;29(suppl_1):i10-i19. doi: 10.1093/annonc/mdx703.

PMID:
29462254
25.

Usefulness of Rapiplug in nipple reconstruction to improve nipple projection.

Lee JS, Kwon JH, Lee JW, Choi KY, Chung HY, Cho BC, Yang JD.

ANZ J Surg. 2018 Feb 8. doi: 10.1111/ans.14410. [Epub ahead of print]

PMID:
29423974
26.

Eyebrow Position and Shape Favored by Korean Women.

Jung GS, Chung KH, Lee JW, Yang JD, Chung HY, Cho BC, Choi KY.

J Craniofac Surg. 2018 May;29(3):594-598. doi: 10.1097/SCS.0000000000004301.

PMID:
29381637
27.

Structure of the Marine Siphovirus TW1: Evolution of Capsid-Stabilizing Proteins and Tail Spikes.

Wang Z, Hardies SC, Fokine A, Klose T, Jiang W, Cho BC, Rossmann MG.

Structure. 2018 Feb 6;26(2):238-248.e3. doi: 10.1016/j.str.2017.12.001. Epub 2017 Dec 28.

PMID:
29290487
28.

Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.

Soo RA, Lim SM, Syn NL, Teng R, Soong R, Mok TSK, Cho BC.

Lung Cancer. 2018 Jan;115:12-20. doi: 10.1016/j.lungcan.2017.11.009. Epub 2017 Nov 13. Review.

PMID:
29290252
29.

Transoral robotic surgery-based therapy in patients with stage III-IV oropharyngeal squamous cell carcinoma.

Park YM, Kim HR, Cho BC, Keum KC, Cho NH, Kim SH.

Oral Oncol. 2017 Dec;75:16-21. doi: 10.1016/j.oraloncology.2017.10.014. Epub 2017 Oct 21.

PMID:
29224814
30.

A Clinical Photographic Method to Evaluate the Need for Helmet Therapy in Deformational Plagiocephaly.

Cho IK, Eom JR, Lee JW, Yang JD, Chung HY, Cho BC, Choi KY.

J Craniofac Surg. 2018 Jan;29(1):149-152. doi: 10.1097/SCS.0000000000004192.

PMID:
29194259
31.

Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers.

Yu HA, Ahn MJ, Cho BC, Gerber DE, Natale RB, Socinski MA, Giri N, Quinn S, Sbar E, Zhang H, Giaccone G.

Lung Cancer. 2017 Oct;112:195-199. doi: 10.1016/j.lungcan.2017.08.017. Epub 2017 Aug 23.

PMID:
29191595
32.

Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization.

Kim HR, Cha YJ, Hong MH, Gandhi M, Levinson S, Jung I, Lee JG, Lee CY, Cho BC, Ha SJ, Shim HS.

Oncotarget. 2017 Aug 14;8(50):87234-87243. doi: 10.18632/oncotarget.20254. eCollection 2017 Oct 20.

33.

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators.

N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.

34.

Impact of Tumor Purity on Immune Gene Expression and Clustering Analyses across Multiple Cancer Types.

Rhee JK, Jung YC, Kim KR, Yoo J, Kim J, Lee YJ, Ko YH, Lee HH, Cho BC, Kim TM.

Cancer Immunol Res. 2018 Jan;6(1):87-97. doi: 10.1158/2326-6066.CIR-17-0201. Epub 2017 Nov 15.

PMID:
29141981
35.

Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.

Lee CK, Kim S, Lee JS, Lee JE, Kim SM, Yang IS, Kim HR, Lee JH, Kim S, Cho BC.

Lung Cancer. 2017 Nov;113:106-114. doi: 10.1016/j.lungcan.2017.09.005. Epub 2017 Sep 12.

PMID:
29110836
36.

Zygomatico-orbital artery: The largest artery in the temporal area.

Choi DH, Eom JR, Lee JW, Yang JD, Chung HY, Cho BC, Choi KY.

J Plast Reconstr Aesthet Surg. 2018 Apr;71(4):484-489. doi: 10.1016/j.bjps.2017.10.003. Epub 2017 Oct 16.

PMID:
29097021
37.

Draft genome sequence of Marinobacterium rhizophilum CL-YJ9T (DSM 18822T), isolated from the rhizosphere of the coastal tidal-flat plant Suaeda japonica.

Choi DH, Jang GI, Lapidus A, Copeland A, Reddy TBK, Mukherjee S, Huntemann M, Varghese N, Ivanova N, Pillay M, Tindall BJ, Göker M, Woyke T, Klenk HP, Kyrpides NC, Cho BC.

Stand Genomic Sci. 2017 Oct 30;12:65. doi: 10.1186/s40793-017-0275-x. eCollection 2017.

38.

A Clinical Trial of Combination Neoadjuvant Chemotherapy and Transoral Robotic Surgery in Patients with T3 and T4 Laryngo-Hypopharyngeal Cancer.

Park YM, Keum KC, Kim HR, Cho BC, Kim DH, Cho NH, Kim SH.

Ann Surg Oncol. 2018 Apr;25(4):864-871. doi: 10.1245/s10434-017-6208-5. Epub 2017 Oct 30.

PMID:
29086129
39.

The usefulness of pedicled perforator flap in partial breast reconstruction after breast conserving surgery in Korean women.

Kim JB, Kim DK, Lee JW, Choi KY, Chung HY, Cho BC, Park HY, Lee JY, Yang JD.

Arch Plast Surg. 2018 Jan;45(1):29-36. doi: 10.5999/aps.2017.01200. Epub 2017 Oct 27.

40.

Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival in Patients Treated With Lung Stereotactic Body Radiation Therapy (SBRT).

Glick D, Lyen S, Kandel S, Shapera S, Le LW, Lindsay P, Wong O, Bezjak A, Brade A, Cho BCJ, Hope A, Sun A, Giuliani M.

Clin Lung Cancer. 2018 Mar;19(2):e219-e226. doi: 10.1016/j.cllc.2017.06.021. Epub 2017 Jul 10.

PMID:
29066051
41.

Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.

Ahn MJ, Kim DW, Cho BC, Kim SW, Lee JS, Ahn JS, Kim TM, Lin CC, Kim HR, John T, Kao S, Goldman JW, Su WC, Natale R, Rabbie S, Harrop B, Overend P, Yang Z, Yang JC.

Lancet Respir Med. 2017 Nov;5(11):891-902. doi: 10.1016/S2213-2600(17)30378-8. Epub 2017 Oct 19.

PMID:
29056570
42.

Normative Values of Physical Examinations Commonly Used for Cerebral Palsy.

Moon SJ, Choi Y, Chung CY, Sung KH, Cho BC, Chung MK, Kim J, Yoo MS, Lee HM, Park MS.

Yonsei Med J. 2017 Nov;58(6):1170-1176. doi: 10.3349/ymj.2017.58.6.1170.

43.

Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck.

Hong MH, Kim CG, Koh YW, Choi EC, Kim J, Yoon SO, Kim HR, Cho BC.

Head Neck. 2018 Jan;40(1):55-62. doi: 10.1002/hed.24933. Epub 2017 Oct 16.

PMID:
29044862
44.

Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis.

Kim CG, Shim HS, Hong MH, Cha YJ, Heo SJ, Park HS, Kim JH, Lee JG, Lee CY, Cho BC, Kim HR.

Oncotarget. 2017 May 10;8(39):65111-65122. doi: 10.18632/oncotarget.17786. eCollection 2017 Sep 12.

45.

Architectural patterns of p16 immunohistochemical expression associated with cancer immunity and prognosis of head and neck squamous cell carcinoma.

Ryu HJ, Kim EK, Heo SJ, Cho BC, Kim HR, Yoon SO.

APMIS. 2017 Nov;125(11):974-984. doi: 10.1111/apm.12744. Epub 2017 Oct 4.

PMID:
28975663
46.

ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.

Yun MR, Choi HM, Kang HN, Lee Y, Joo HS, Kim DH, Kim HR, Hong MH, Yoon SO, Cho BC.

Oncogene. 2018 Jan 18;37(3):377-388. doi: 10.1038/onc.2017.339. Epub 2017 Sep 25.

PMID:
28945228
47.

Survival Impact of Cardiac Dose Following Lung Stereotactic Body Radiotherapy.

Wong OY, Yau V, Kang J, Glick D, Lindsay P, Le LW, Sun A, Bezjak A, Cho BCJ, Hope A, Giuliani M.

Clin Lung Cancer. 2018 Mar;19(2):e241-e246. doi: 10.1016/j.cllc.2017.08.002. Epub 2017 Aug 31.

PMID:
28941961
48.

Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01).

Kim HR, Jang JS, Sun JM, Ahn MJ, Kim DW, Jung I, Lee KH, Kim JH, Lee DH, Kim SW, Cho BC.

Oncotarget. 2017 Aug 14;8(33):55766. doi: 10.18632/oncotarget.20268. eCollection 2017 Aug 15.

49.

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M; PACIFIC Investigators.

N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8.

50.

Radiotherapy for the treatment of malignant pleural mesothelioma.

Perrot M, Wu L, Wu M, Cho BCJ.

Lancet Oncol. 2017 Sep;18(9):e532-e542. doi: 10.1016/S1470-2045(17)30459-X. Review.

PMID:
28884702

Supplemental Content

Loading ...
Support Center